GlassScriptPhysician profile
Richard C Costa
NPI 1982693511
$8,439.15
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,992 · 2020: $2,410 · 2021: $2,407 · 2022: $1,216 · 2023: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $847.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $807.88 | 2019-2023 | Breztri |
| Abbvie INC. | $704.41 | 2019-2022 | |
| Novo Nordisk INC | $695.47 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $648.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $494.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $482.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $407.29 | 2019-2023 | Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.92 | 2019-2022 | |
| Pfizer INC. | $315.72 | 2019-2023 | |
| Axsome Therapeutics, INC. | $257.52 | 2023 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $234.93 | 2019-2023 | Seglentis, Livalo |
| Allergan, INC. | $224.86 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $185.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $174.30 | 2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.